SANA Fundamental Analysis - SANA BIOTECHNOLOGY INC

Fundamental Rating

Taking everything into account, SANA scores 2 out of 10 in our fundamental rating. SANA was compared to 557 industry peers in the Biotechnology industry. While SANA seems to be doing ok healthwise, there are quite some concerns on its profitability. SANA does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

SANA had negative earnings in the past year.

In the past year SANA has reported a negative cash flow from operations.

In the past 5 years SANA always reported negative net income.

In the past 5 years SANA always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -46.84%, SANA perfoms like the industry average, outperforming 51.17% of the companies in the same industry.

Looking at the Return On Equity, with a value of -99.81%, SANA is in line with its industry, outperforming 45.96% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-46.84%
ROE	-99.81%
ROIC	N/A

ROA(3y)-45.37%

ROA(5y)-41.34%

ROE(3y)-86.33%

ROE(5y)-74.79%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SANA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SANA has more shares outstanding than it did 1 year ago.

SANA has more shares outstanding than it did 5 years ago.

SANA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

SANA has an Altman-Z score of -4.20. This is a bad value and indicates that SANA is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of SANA (-4.20) is comparable to the rest of the industry.

There is no outstanding debt for SANA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-4.2

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

SANA has a Current Ratio of 3.40. This indicates that SANA is financially healthy and has no problem in meeting its short term obligations.

SANA has a worse Current ratio (3.40) than 60.14% of its industry peers.

A Quick Ratio of 3.40 indicates that SANA has no problem at all paying its short term obligations.

SANA has a Quick ratio (3.40) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	3.4
Quick Ratio	3.4

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

SANA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.14%, which is quite impressive.

EPS 1Y (TTM)40.14%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%57.14%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 6.45% on average over the next years.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y32.61%

EPS Next 2Y16.28%

EPS Next 3Y9.31%

EPS Next 5Y6.45%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SANA. In the last year negative earnings were reported.

Also next year SANA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y16.28%

EPS Next 3Y9.31%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

SANA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SANA BIOTECHNOLOGY INC

NASDAQ:SANA (7/11/2025, 8:00:02 PM)

After market: 4.1601 -0.02 (-0.48%)

4.18

+0.12 (+2.96%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-08 2025-05-08/amc

Earnings (Next)07-31 2025-07-31/amc

Inst Owners89.23%

Inst Owner Change0%

Ins Owners8.27%

Ins Owner Change0.3%

Market Cap942.84M

Analysts84.29

Price Target9.52 (127.75%)

Short Float %21.19%

Short Ratio11.16

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)9.68%

Min EPS beat(2)9.03%

Max EPS beat(2)10.32%

EPS beat(4)4

Avg EPS beat(4)12.24%

Min EPS beat(4)1.83%

Max EPS beat(4)27.76%

EPS beat(8)5

Avg EPS beat(8)7.62%

EPS beat(12)9

Avg EPS beat(12)11.29%

EPS beat(16)12

Avg EPS beat(16)10.69%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-1.75%

PT rev (3m)-1.75%

EPS NQ rev (1m)0%

EPS NQ rev (3m)11.66%

EPS NY rev (1m)0%

EPS NY rev (3m)16.32%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	4.51
P/tB	101.85
EV/EBITDA	N/A

EPS(TTM)-0.88

EYN/A

EPS(NY)-0.75

Fwd EYN/A

FCF(TTM)-0.99

FCFYN/A

OCF(TTM)-0.91

OCFYN/A

SpS0

BVpS0.93

TBVpS0.04

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-46.84%
ROE	-99.81%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-45.37%

ROA(5y)-41.34%

ROE(3y)-86.33%

ROE(5y)-74.79%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	102.47%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.4
Quick Ratio	3.4
Altman-Z	-4.2

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)135.8%

Cap/Depr(5y)216.07%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)40.14%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%57.14%

EPS Next Y32.61%

EPS Next 2Y16.28%

EPS Next 3Y9.31%

EPS Next 5Y6.45%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y35.08%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year31.03%

EBIT Next 3Y4.22%

EBIT Next 5YN/A

FCF growth 1Y27.1%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y29.3%

OCF growth 3YN/A

OCF growth 5YN/A

SANA BIOTECHNOLOGY INC (SANA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens